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A B S T R A C T
Purpose
Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However,
objective measures of cardiac function and health-related quality of life are lacking in long-term
follow-up of patients who remain cancer free after completion of adjuvant treatment.
Patients and Methods
Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without
trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor
2–positive early-stage breast cancer. A long-term follow-up assessmentwas undertaken for patients
whowere alive and disease free, which includedmeasurement of left ventricular ejection fraction by
multigated acquisition scan along with patient-reported outcomes using the Duke Activity Status
Index (DASI), the Medical Outcomes Study questionnaire, and a review of current medications and
comorbid conditions.
Results
At amedian follow-up of 8.8 years among eligible participants, five (4.5%) of 110 in the control group
and 10 (3.4%) of 297 in the trastuzumab group had a . 10% decline in left ventricular ejection
fraction from baseline to a value , 50%. Lower DASI scores correlated with age and use of
medications for hypertension, cardiac conditions, diabetes, and hyperlipidemia, but not with
whether patients had received trastuzumab.
Conclusion
In patients without underlying cardiac disease at baseline, the addition of trastuzumab to adjuvant
anthracycline and taxane-based chemotherapy does not result in long-term worsening of cardiac
function, cardiac symptoms, or health-related quality of life. The DASI questionnaire may provide
a simple and useful tool for monitoring patient-reported changes that reflect cardiac function.
J Clin Oncol 35:3942-3948. © 2017 by American Society of Clinical Oncology
INTRODUCTION
NSABP (National Surgical Adjuvant Breast and
Bowel Project) Protocol B-31 tested whether the
addition of the monoclonal antibody trastuzu-
mab to standard paclitaxel after doxorubicin and
cyclophosphamide (AC) chemotherapy would
improve disease-free or overall survival in patients
with human epidermal growth factor receptor 2
(HER2)–positive breast cancer. Planned com-
bined efficacy joint analysis with the similar
NCCTG (North Central Cancer Treatment
Group) N9831 trial demonstrated a 10-year
overall survival of 84% with a hazard ratio of 0.63
with the addition of the antibody to adjuvant
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chemotherapy.1 Cardiotoxicity was recognized as an important
potential toxicity in the design of B-31,2,3 and with 7 years of
follow-up, the cumulative incidence of severe cardiac events was
significantly increased (4.0% v 1.3%) with the addition of tras-
tuzumab. However, severe cardiotoxicity seemed to be an early
event, because only two cases of congestive heart failure (CHF)
occurred . 2 years after initiation of trastuzumab.4
Little is known about the cardiac function, health-related
quality of life (HR-QoL), and symptoms in long-term survivors
of anthracycline-based adjuvant chemotherapy with or without
trastuzumab. The B-31 trial provided an opportunity to assess these
outcomes in a well-characterized cohort of patients. We report here
the results of an amendment to the B-31 protocol, which recruited
breast cancer–free survivors for long-term follow-up (LTF) assess-
ments of cardiac function, patient-reported outcomes (PROs) re-
lated to HR-QoL, and cardiac-related symptoms and morbidity.
PATIENTS AND METHODS
Patients in B-31 had HER2-positive, node-positive operable breast cancer
and received four cycles of AC (60/600 mg/m2 every 3 weeks) followed by
paclitaxel (175 mg/m2 every 3 weeks for four cycles or 80 mg/m2 weekly for
12 weeks). Patients randomly assigned to the investigational group also
received trastuzumab at 4mg/kg concurrently with the first dose of paclitaxel
followed by 2 mg/kg weekly for a total of 52 weeks. Those with hormone
receptor–positive tumors initiated adjuvant endocrine therapy after com-
pletion of chemotherapy. Patients with a history or current diagnosis of the
following were excluded: angina pectoris, cardiac arrhythmia, severe con-
duction abnormality, significant valvular disease, cardiomegaly, ventricular
hypertrophy, uncontrolled hypertension, myocardial infarction, CHF, or
cardiomyopathy. Cardiac function was monitored using left ventricular
ejection fraction (LVEF) measured by multigated acquisition (MUGA) scans
at 3, 6, 9, and 18 months after random assignment. Rules for holding or
stopping trastuzumab were based on the 3-, 6-, and 9-month assessments.
AlthoughMUGA scans were not planned beyond 18months, cardiac history
forms were collected every 6 months for the first 5 years and annually
thereafter to identify late cardiac morbidity.
The protocol was amended in 2010 to offer survivors without re-
currence the opportunity to respond to a single PRO questionnaire and
undergo MUGA scans between 5 and 10 years after random assignment. To
be eligible for the LTF study, participants had to be disease free from breast
cancer or second primary malignancy, have 18-month LVEF data available,
have received only the assigned B-31 therapy (ie, patients in the control group
not having received trastuzumab subsequent to reporting of the initial B-31/
N9831 results), and provide written informed consent for the LTF study.
Recruitment of Sites and Participants
Participating institutions were provided the amended protocol and
consent form for submission to their institutional review boards (IRBs)
with a list of potential patients for LTF evaluation at their sites. After IRB
approval, sites were requested to approach all potentially eligible patients
and obtain signed consent forms from those who agreed to participate.
Patients who consented were requested to complete the PRO questionnaire
and then undergo LVEF assessment by MUGA scan. Patients were also
asked to complete an updated cardiac history form within a 2-month
window around PRO questionnaire completion.
Questionnaire Survey Content
The survey battery included four instruments. The first was the
36-itemMedical Outcomes Study short-form questionnaire (MOS-SF36),5
which has eight subscales with normative data available from the general
population.6 MOS-SF36 can also be scored as two component summary
scales that measure physical (PCS) and mental (MCS) functioning. These
are presented as T scores, with a normal healthy population mean score of
50 and standard deviation (SD) of 10. The Duke Activity Status Index
(DASI),7,8 a validated 12-item self-report questionnaire widely used to
determine functional capacity among individuals with cardiac disease, was
also used. The DASI score correlates with function and oxygen capacity
during exercise testing and provides metabolic equivalents for level of
activity.7 DASI scores range from 0 to 58.2, with higher scores indicating
better functional capacity.9 Chronic comorbid conditions were assessed
with a questionnaire developed by Sangha et al.10 Finally, participants were
asked separately about common symptoms associated with cardiac disease,
with items taken from the Breast Cancer Prevention Trial symptom
checklist (chest pain, feeling of suffocation, difficulty breathing, shortness
of breath, swelling of hands and feet, and dizziness or faintness), which
were rated as follows for severity of bother: not at all, 0; slightly, 1; mod-
erately, 2; quite a bit, 3; and extremely, 4.11
Clinical staff also recorded data on the cardiac history form used
throughout the B-31 study. This form asked whether the patient had taken
medication for any of the following conditions since the last follow-up:
hypertension, angina, myocardial infarction, CHF, cardiomyopathy, atrial
fibrillation or atrial arrhythmias, ventricular arrhythmias, diabetes, or
elevated fasting lipid profile. Smoking activity was also assessed.
Statistical Methods
The primary aim of the LTF evaluation was to assess the long-term
effect of trastuzumab on LVEF 5 to 10 years after study entry by comparing
the proportion of patients who received chemotherapy plus trastuzumab
and experienced a significant LVEF decline (absolute drop in LVEF from
baseline $ 10% to a value , 50%) at the LTF evaluation with the pro-
portion in the control group treated with chemotherapy without trastu-
zumab. Given our obtained sample size, we had 80% power to detect
a difference in proportions of 0.073 between treatment groups at a two-
sided significance level of .05. A secondary aim was to compare the
proportions of patients with LVEF values . 50% at 18 months that de-
clined to , 40% at LTF between the two treatment groups.
Randomly assigned to B-31
(N = 2,119)
Completed PRO questionnaire
(n = 268)
Completed PRO questionnaire
(n = 98)
Long-term MUGA
(n = 297)
Long-term MUGA
(n = 110)
Consented
(n = 313)
Consented
(n = 128)
Eligible for LTF
(n = 631)
Eligible for LTF
(n = 332)
AC  PH
(n = 1,058)
AC  P
(n = 1,061)
Fig 1. Flowof participants of NSABP (National Surgical Adjuvant Breast and Bowel
Project) B-31 long-term cardiac follow-up. AC, doxorubicin and cyclophosphamide; H,
trastuzumab; LTF, long-term follow-up; MUGA, multigated acquisition; P, paclitaxel;
PRO, patient-reported outcome.
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Other secondary aims were to determine the long-term effects of the
B-31 treatments on HR-QoL, cardiac performance, and comorbid health
problems among disease-free survivors. We evaluated the descriptive
statistics of the MOS-SF36 MCS and PCS scores and the DASI score overall
and by treatment group. Responses to the questions regarding current
cardiac medications, cardiac symptoms, and comorbid conditions by
treatment group were also compared using the x2 test. An overall score of
the comorbidity questionnaire was calculated according to the method by
Sangha et al.10 Briefly, a patient can receive three points for each condition:
one point for the presence of the condition, one point for treatment, and
one point if the condition limits activities. The possible range of scores is
0 to 60, with higher score indicating a greater impact of comorbidities.
We also explored the distribution of DASI scores after noting the
large SD and range of the scores. Although a majority of patients re-
ported few limitations in functioning, there was a substantial group for
whom poor functioning was observed. We therefore examined the re-
lationship between the lower tertile scores on DASI and the remainder of
the sample to characterize those women reporting relevant cardiac
dysfunction at this LTF assessment. Treatment group; age at entry;
baseline use of hypertension, diabetes, or hyperlipidemia medications;
smoking history; side irradiated; and LVEF values at baseline, 18 months,
and LTF were compared between the two DASI groups using the x2 test.
Mean PCS, MCS, and metabolic equivalent scores as well as current use
of cardiac medications were also compared between the two DASI
groups. We also used multivariable logistic regression to identify pre-
dictors of poorer DASI score. The explanatory variables considered for
inclusion were treatment group; age at entry; baseline use of hyper-
tension, diabetes, or hyperlipidemia medications; smoking history; side
irradiated; and LVEF values at baseline, 18 months, and LTF. Time from
random assignment to completion of the PRO questionnaire and
assigned treatment group were also included in the final model to control
for potential confounding. All P values reported were two sided, with
a significance level of .05. Analyses were performed using SAS software
(version 9.2; SAS Institute, Cary, NC).
Table 1. Patient Characteristics: NSABP B-31 Long-Term Cardiac Follow-Up
Characteristic
All Eligible
Eligible, Not
Consented
Eligible, Consented
PRO
Participant*AC → P AC → PH Total
No. % No. % No. % No. % No. % No. %
Age at entry, years
, 50 481 49.9 264 50.6 62 48.4 155 49.5 217 49.2 179 48.9
50-59 330 34.3 169 32.4 48 37.5 113 36.1 161 36.5 133 36.3
$ 60 152 15.8 89 17.0 18 14.1 45 14.4 63 14.3 54 14.8
Race
White 799 83.0 422 80.8 109 85.2 268 85.6 377 85.5 315 86.1
Hispanic 35 3.6 18 3.4 5 3.9 12 3.8 17 3.9 14 3.8
Black 83 8.6 52 10.0 12 9.4 19 6.1 31 7.0 27 7.4
Other 16 1.7 10 1.9 0 0 6 1.9 6 1.4 4 1.1
Asian 27 2.8 18 3.4 2 1.6 7 2.2 9 2.0 5 1.4
Unknown 3 0.3 2 0.4 0 0 1 0.3 1 0.2 1 0.3
Baseline hypertension medication use
Yes 205 21.3 120 23.0 22 17.2 63 20.1 85 19.3 72 19.7
No 754 78.3 401 76.8 105 82.0 248 79.2 353 80.0 291 79.5
Unknown 4 0.4 1 0.2 1 0.8 2 0.6 3 0.7 3 0.8
Baseline diabetes medication use
Yes 37 3.8 23 4.4 5 3.9 9 2.9 14 3.2 13 3.6
No 922 95.7 498 95.4 122 95.3 302 96.5 424 96.1 350 95.6
Unknown 4 0.4 1 0.2 1 0.8 2 0.6 3 0.7 3 0.8
Baseline elevated fasting lipid profile medication use
Yes 86 8.9 41 7.9 17 13.3 28 8.9 45 10.2 37 10.1
No 863 89.6 473 90.6 109 85.2 281 89.8 390 88.4 323 88.3
Unknown 14 1.5 8 1.5 2 1.6 4 1.3 6 1.4 6 1.6
History of smoking
Yes 362 37.6 198 37.9 49 38.3 115 36.7 164 37.2 133 36.3
No 596 61.9 323 61.9 78 60.9 195 62.3 273 61.9 229 62.6
Unknown 5 0.5 1 0.2 1 0.8 3 1.0 4 0.9 4 1.1
Irradiation
None or right side 592 61.5 318 60.9 78 60.9 196 62.6 274 62.1 225 61.5
Left side 364 37.8 200 38.3 50 39.1 114 36.4 164 37.2 140 38.3
Unknown 7 0.7 4 0.8 0 0 3 1.0 3 0.7 1 0.3
Baseline LVEF, %
$ 65 441 45.8 224 42.9 69 53.9 148 47.3 217 49.2 183 50.0
55-64 448 46.5 257 49.2 48 37.5 143 45.7 191 43.3 155 42.3
50-54 71 7.4 40 7.7 11 8.6 20 6.4 31 7.0 26 7.1
, 50 3 0.3 1 0.2 0 0 2 0.6 2 0.5 2 0.5
18-month LVEF, %
$ 65 291 30.2 167 32.0 37 28.9 87 27.8 124 28.1 107 29.2
55-64 473 49.1 251 48.1 71 55.5 151 48.2 222 50.3 190 51.9
50-54 125 13.0 65 12.5 14 10.9 46 14.7 60 13.6 44 12.0
, 50 74 7.7 39 7.5 6 4.7 29 9.3 35 7.9 25 6.8
Total 963 100.0 522 100.0 128 100.0 313 100.0 441 100.0 366 100.0
Abbreviations: AC, doxorubicin and cyclophosphamide; H, trastuzumab; LVEF, left ventricular ejection fraction; NSABP, National Surgical Adjuvant Breast and Bowel
Project; P, paclitaxel; PRO, patient-reported outcome.
*Patients who completed the PRO questionnaire.
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RESULTS
Patient Eligibility and Baseline Characteristics
Of the 2,119 patients enrolled in B-31, 963 were eligible to
participate in the LTF study (Fig 1). Fewer patients in the control
group were eligible as a result of a greater likelihood of breast
cancer recurrence, as well as the subsequent receipt of trastuzumab
after the results of the B-31/N9831 analysis were made public.
Recruitment of eligible long-term survivors was not as successful as
hoped, which has been reported in similar efforts.12,13 Of those
eligible to participate, 441 (45.8%) consented to participate
(control group, 38.6%; trastuzumab group, 49.6%) and are the
subject of this report.
Patient characteristics between consented patients and the
entire cohort of eligible LTF patients and between the two treat-
ment groups among those who consented to participate in LTF
were similar (Table 1). Also, the baseline characteristics of the LTF
cohort were similar to those of the entire B-31 population, as
previously reported.14 We received LTF MUGA scan results from
407 of the 441 consented patients (control group, n = 110; tras-
tuzumab group, n = 297). At the time of the LTF assessment, the
mean age of the patients was 58.3 years, and median follow-up was
8.8 years (range, 5.6 to 13.8 years).
LVEF Results and Cardiovascular Medication Use at LTF
The mean LVEF measurements at baseline, 18 months, and
LTF assessments are shown in Figure 2. At 18 months, the mean
decline from baseline was 3.2% in the control group and 3.9% in
the trastuzumab group. At the LTF assessments, the mean decline
from baseline was 3.9% versus 2.8%, respectively.
Among the control group LTF participants, three (2.7%) of
110 had a reported decline of $ 10% to, 50% at their 18-month
assessment compared with 23 (7.7%) of 297 in the trastuzumab
group. At the LTF assessment, this decline was reported in five (4.5%)
of 110 in the control group versus 10 (3.4%) of 297 in the trastu-
zumab group. Only one patient in the control group and two in the
trastuzumab group with LVEF measurements . 50% at 18 months
had measurements, 40% at LTF (Appendix Table A1, online only).
Approximately 19% of the LTF participants were receiving
antihypertensive medications at entry in B-31. At the LTF as-
sessment, antihypertensive medications were being used by 31.8%
in the control group and 33.3% in the trastuzumab group. Specific
reasons for medication use are listed in Appendix Table A2 (online
Baseline 18 months LTF
Time Point
55
60
65
70
LV
EF
 (%
)
Not consented, AC P
Not consented, AC PH
LTF participant, AC PH
LTF participant, AC P
Fig 2. Mean left ventricular ejection fraction (LVEF) measurements over time for
National Surgical Adjuvant Breast and Bowel Project B-31 long-term cardiac follow-
up participants and those who were eligible but did not consent. Vertical bars
represent 95% CIs. AC, doxorubicin and cyclophosphamide; H, trastuzumab; LTF,
long-term follow-up; P, paclitaxel.
Table 2. Patient Characteristics by DASI Score: NSABP B-31 Long-Term
Cardiac Follow-Up
Characteristic
No. of
Patients
DASI Score
P
, 43
(n = 126)
$ 43
(n = 216)
No. % No. %
Treatment .13
AC → P 95 41 32.5 54 25.0
AC → PH 247 85 67.5 162 75.0
Age at entry, years , .001
, 50 166 28 22.2 138 63.9
50-59 128 66 52.4 62 28.7
$ 60 48 32 25.4 16 7.4
Baseline hypertension
medication use
, .001
No 271 81 65.3 190 88.4
Yes 68 43 34.7 25 11.6
Baseline diabetes
medication use
.24
No 326 117 94.4 209 97.2
Yes 13 7 5.6 6 2.8
Baseline elevated lipid
profile medication use
.002
No 301 102 82.9 199 93.4
Yes 35 21 17.1 14 6.6
History of smoking .11
No 215 72 58.1 143 66.8
Yes 123 52 41.9 71 33.2
Irradiation .11
None or right side 211 71 56.3 140 65.1
Left side 130 55 43.7 75 34.9
Baseline LVEF, % .95
$ 65 173 65 51.6 108 50.0
55-64 143 52 41.3 91 42.1
, 55 26 9 7.1 17 7.9
18-month LVEF, % .07
$ 65 102 41 32.5 61 28.2
55-64 177 62 49.2 115 53.2
50-54 40 10 7.9 30 13.9
, 50 23 13 10.3 10 4.6
Long-term LVEF, % .10
$ 65 123 48 38.1 75 34.7
55-64 167 54 42.9 113 52.3
50-54 34 13 10.3 21 9.7
, 50 18 11 8.7 7 3.2
Mean (SD)
MOS-SF36 PCS
340 43.0 (9.0) 54.1 (5.6) , .001
Mean (SD)
MOS-SF36 MCS
340 49.5 (12.0) 55.4 (6.1) , .001
Mean (SD)
MET
342 6.4 (1.2) 9.5 (0.6) , .001
Abbreviations: AC, doxorubicin and cyclophosphamide; DASI, Duke Activity
Status Index; H, trastuzumab; LVEF, left ventricular ejection fraction; MCS,
mental component score; MOS-SF36, 36-item Medical Outcomes Study short-
form questionnaire; NSABP, National Surgical Adjuvant Breast and Bowel
Project; P, paclitaxel; PCS, physical component score; SD, standard deviation;
MET, metabolic equivalent.
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only). Nonsmokers comprised 92.6% of the LTF patients (data not
shown).
In our previous report,4 37 patients in the trastuzumab group
had experienced a cardiac event, including one cardiac death. Of
these, 23 were eligible for the LTF study, and only eight consented
to participate. Six of these eight had LTF LVEF measurements
. 50%, and five were within 5 percentage points of their baseline
values (data not shown). Ten of the 37 patients have died, four
subsequent to our previous report. One of these patients was not
eligible for the LTF study because of an earlier second primary
cancer diagnosis (cause of death unknown), two were eligible but
did not consent (one cause of death was unknown, and the other
resulted from injury), and one participated in the LTF but later died
as a result of lung cancer.
QoL and PROs
Of the 407 patients with LTF LVEF assessments, 366 (89.9%)
also completed PRO questionnaires (control group, n = 98;
trastuzumab group, n = 268). The median time from random
assignment to questionnaire completion was 8.7 years (range, 5.5
to 14 years). We first examined the descriptive statistics for the
MCS and PCS scores of MOS-SF36 and the DASI score according
to treatment assignment. The scores for both groups were high
(favorable), reflecting higher-than-expected physical and mental
functioning compared with reference populations of the same age.
The mean PCS score for all patients was 49.7 (SD, 9.1), and the
meanMCS score was 52.9 (SD, 9.4). Themean DASI score was 45.6
(SD, 13.8; range, 7.2 to 58.2) for the total sample. We also
compared common cardiac symptoms and lifetime comorbid
conditions by treatment group.We found no statistically significant
differences between treatment groups for any individual symptom
or condition or for the overall comorbidity score. The mean
comorbidity score was 4.77 (SD, 3.61) in the control arm and 4.87
(SD, 4.22) in the trastuzumab arm (data not shown).
On the basis of the wide distribution of the DASI scores, we
categorized patients into two groups representing those with the
lowest tertile of DASI scores (, 43) versus the remainder of the
sample ($ 43) to characterize women reporting relevant cardiac
dysfunction at the LTF assessment. Table 2 shows the relationship
between key patient characteristics according to the categorized
DASI score. There were statistically significant relationships be-
tween age group (P , .001), baseline hypertensive medication use
(P, .001), baseline hyperlipidemia medication use (P = .002), and
DASI score, with older patients and patients using medication at
baseline reporting more dysfunction. Those with the lowest DASI
scores had a lower but nonsignificant 18-month LVEF (P = .07).
There were also no significant differences by treatment assignment,
baseline diabetes medication use, smoking history, left-sided ir-
radiation, baseline LVEF, or LTF LVEF. The patients in the lowest
tertile of DASI scores demonstrated poorer physical and mental
MOS-SF36 scores than those with higher DASI scores (P , .001).
We performed multivariable logistic regression analyses to
examine which variables were associated with the lowest tertile
DASI scores at the LTF visit. Variables included were treatment
assignment and those that were significant (P , .10) in the
bivariable analyses. We also included time from random assign-
ment to the completion of the PRO questionnaire because of the
large range of completion times. Results of the model are listed in
Table 3. Variables significantly associated with poorer cardiac
function at the LTF assessment were older age at protocol entry and
baseline antihypertensive medication use. Treatment assignment
was not associated with poorer cardiac function and was in fact
numerically better in the trastuzumab group. An 18-month
LVEF , 50% showed a statistically insignificant trend with an
increased odds ratio of 2.69 (95% CI, 0.97 to 7.43; P = .06).
We also examined cardiovascular medication use at LTF as-
sessment according to DASI score (Table 4) and found additional
support for the validity of the DASI score in that patients in the
lowest tertile were more likely to be taking medication for
Table 3. Multivariable Model for Predicting Low DASI Score (, 43): NSABP B-31 Long-Term Cardiac Follow-Up
Characteristic No. of Patients
DASI Score
P OR 95% CI
, 43
(n = 126)
$ 43
(n = 216)
No. % No. %
Treatment
AC → P 95 41 32.5 54 25.0 Ref
AC → PH 247 85 67.5 162 75.0 .07 0.59 0.34 to 1.04
Mean (SD) time to form completion, months 342 104.3 (19.1) 103.3 (18.0) .14 1.01 0.997 to 1.03
Mean (SD) age at entry, years 342 54.7 (8.5) 46.9 (8.6) , .001 1.10 1.06 to 1.13
Baseline hypertension medication use
No 271 81 65.3 190 88.4 Ref
Yes 68 43 34.7 25 11.6 .007 2.38 1.27 to 4.47
Baseline elevated lipid profile medication use
No 301 102 82.9 199 93.4 Ref
Yes 35 21 17.1 14 6.6 .12 1.92 0.85 to 4.36
18-month LVEF, %
$ 65 102 41 32.5 61 28.2 Ref
55-64 177 62 49.2 115 53.2 .62 0.87 0.49 to 1.53
50-54 40 10 7.9 30 13.9 .27 0.59 0.24 to 1.50
, 50 23 13 10.3 10 4.6 .06 2.69 0.97 to 7.43
Abbreviations: AC, doxorubicin and cyclophosphamide; DASI, Duke Activity Status Index; H, trastuzumab; LVEF, left ventricular ejection fraction; NSABP, National
Surgical Adjuvant Breast and Bowel Project; OR, odds ratio; P, paclitaxel; Ref, referent; SD, standard deviation.
3946 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ganz et al
hypertension (52.4% v 22.7%), CHF (5.6% v 0.0%), as well as any
cardiac-related medication (64.3% v 36.1%). Thus, the self-
reported cardiac function on the DASI questionnaire seemed to
accurately reflect the degree of cardiac morbidity in these long-
term survivors of breast cancer.
DISCUSSION
Cardiac toxicity has been a central consideration in clinical trials
evaluating HER2-targeted therapies. Although these studies have
carefully documented the cumulative incidence of severe and
less severe cardiac dysfunction, long-term assessments of LVEF,
HR-QoL, and PRO reporting of cardiac symptoms have been
unavailable. To our knowledge, this study is the first to provide LTF
measurements of all three of these elements in a well-characterized
cohort of HER2-positive breast cancer survivors who remain alive
and free of breast cancer recurrence at a median of 8.8 years after
treatment initiation. It is also one of the largest long-term studies of
cardiac outcomes in patients treated with anthracyclines with or
without trastuzumab.12 A limitation is that this LTF study does not
provide data from all eligible B-31 patients. Nevertheless, the
patients who participated had baseline clinical characteristics
similar to those of the overall eligible cohort. In addition, their
baseline and 18-month LVEF data were no different from those of
the eligible women who did not participate in the LTF study.
Our study demonstrated no detrimental effect on LVEF from
the addition of trastuzumab to AC plus paclitaxel chemotherapy
among B-31 LTF participants. There was no difference between the
baseline and 18-month LVEF in LTF participants and non-
participants, and the LTF participants showed no late decline in
LVEF. With a median follow-up of 8.8 years, 95.3% of patients
randomly assigned to receive trastuzumab had ejection fractions
$ 50%, and only two (0.6%) of 297 had LVEF# 40%. These results
are consistent with prior observations that cardiac effects of
trastuzumab are generally reversible and qualitatively different
from anthracycline-induced cardiomyopathy.15 It is important to
emphasize, however, that the median age at study entry for patients
in this trial was 50 years, and rules for temporary holding or
discontinuation of trastuzumab based on careful cardiac moni-
toring were strictly observed. Also, although echocardiogram
provides more sensitive assessment of cardiac function, MUGA
scans were used for this LTF study because of the primary end point
and because baseline and 18-month measurements of LVEF were
conducted with this method in all patients.
We have also demonstrated the potential value of including
PROs along with physiologic measures of cardiac function in
follow-up of breast cancer survivors who have received cardiotoxic
treatments. Baseline characteristics of older age and use of anti-
hypertensive medications were predictors of lower DASI score at
LTF assessment, consistent with their reported association with
cardiac events in this clinical trial and other studies.4,16,17 We also
provide evidence for the validity of the DASI questionnaire in this
patient population, because womenwith scores in the lowest tertile
were more likely to require cardiac-related medications at LTF
assessment. Serial follow-up of patients with this 12-item ques-
tionnaire could be used to identify patient-perceived changes in
cardiac performance more frequently than imaging studies. Pro-
spective studies are warranted to evaluate use of the DASI ques-
tionnaire to identify declines in function, which could trigger
formal cardiac function assessments.
Population-based, retrospective, and observational studies
have raised concerns that trastuzumab-related cardiac toxicity in
routine practice may be greater than that seen in clinical trials,
especially in older women even without anthracycline use.18,19
However, these studies do not provide information regarding long-
term cardiac outcomes or HR-QoL measures in patients who
survive without recurrence, underscoring the importance of long-
term cardiac follow-up of women enrolled in trials. Our report
provides encouraging data from the B-31 study and indicates that
in breast cancer survivors without a pre-existing cardiac history,
the addition of trastuzumab to adjuvant anthracycline-based
chemotherapy does not result in long-term worsening of cardiac
function, cardiac symptoms, or HR-QoL.
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Appendix
Table A1. LVEF Measurements and CV-Related Medication Use for Participants With LVEF Decline $ 10% From Baseline to LTF and Long-Term LVEF , 50%
Patient Treatment*
LVEF CV Medication
Baseline 18 Months LTF Use Details
1 1 77 62 48 Yes Hypertension, angina, CHF
2 1 65 55 49 Yes Elevated lipids
3 1 60 57 43 No NA
4 1 62 60 24 Yes Hypertension, CHF, cardiomyopathy, atrial fibrillation
5 1 62 68 44 Yes Diabetes
6 2 56 53 38 Yes Hypertension, elevated lipids
7 2 67 57 44 Yes Diabetes, elevated lipids
8 2 55 55 45 Yes Hypertension, diabetes
9 2 68 60 49 No NA
10 2 60 59 48 Yes Diabetes
11 2 71 51 49 No NA
12 2 61 47 47 Yes Hypertension, elevated lipids
13 2 56 45 42 No NA
14 2 70 52 34 Yes Hypertension, CHF, elevated lipids
15 2 65 61 45 No NA
Abbreviations: CHF, congestive heart failure; CV, cardiovascular; LTF, long-term follow-up; LVEF, left ventricular ejection fraction; NA, not applicable.
*Treatment 1, doxorubicin and cyclophosphamide plus paclitaxel; treatment 2, doxorubicin and cyclophosphamide plus paclitaxel and trastuzumab.
Table A2. CV-Related Medication Use at Time of LTF Evaluation by Condition
and Treatment Group
Condition
AC → P AC → PH Total
No. % No. % No. %
Hypertension 35 31.8 99 33.3 134 32.9
Angina 1 0.9 2 0.7 3 0.7
Myocardial infarction 0 0.0 1 0.3 1 0.2
CHF 2 1.8 5 1.7 7 1.7
Cardiomyopathy 2 1.8 2 0.7 4 1.0
Atrial fibrillation or arrhythmia 5 4.5 3 1.0 8 2.0
Ventricular arrhythmia 2 1.8 0 0.0 2 0.5
Diabetes 11 10.0 27 9.1 38 9.3
Elevated fasting lipid profile 23 20.9 65 21.9 88 21.6
Any CV-related medication use 51 46.4 131 44.1 182 44.7
Abbreviations: AC, doxorubicin and cyclophosphamide; CHF, congestive heart
failure; CV, cardiovascular; H, trastuzumab; LTF, long-term follow-up; P, paclitaxel.
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